RAYMOND ALEXANIAN, M.D.; BART BARLOGIE, M.D.; DENNIS DIXON, M.D.
Grant support: by grants CA 28771 and CA 37161 from the National Cancer Institute.
▸Requests for reprints should be addressed to Raymond Alexanian, M.D.; Department of Hematology, Box 1, M. D. Anderson Hospital and Tumor Institute, 6723 Bertner Avenue; Houston, TX 77030.
ALEXANIAN R, BARLOGIE B, DIXON D. High-Dose Glucocorticoid Treatment of Resistant Myeloma. Ann Intern Med. 1986;105:8-11. doi: 10.7326/0003-4819-105-1-8
Download citation file:
Published: Ann Intern Med. 1986;105(1):8-11.
Intermittent, high-dose dexamethasone treatment was given to 49 consecutive patients with refractory multiple myeloma. In patients who were unresponsive to previous treatment, the response rate of 27% was similar to that achieved with the VAD regimen, which combines the same schedule of dexamethasone with vincristine and doxorubicin given by continuous infusion. Among patients with relapses, VAD chemotherapy induced remissions in 11 of 17 patients (65%), whereas dexamethasone alone induced remissions in 4 of 19 (21%). The median survival of all patients responding to either treatment, 22 months, was longer than that from any previous program for treatment of resistant myeloma. These findings indicate the value of frequent dexamethasone administration in patients unresponsive to standard therapy and show the major role of vincristine and doxorubicin given by continuous infusion in patients with relapses. They also suggest different mechanisms for primary and secondary resistance to chemotherapy.
Learn more about subscription options.
Register Now for a free account.
Hematology/Oncology, Multiple Myeloma.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only